ATM Signalling and Cancer

Total Page:16

File Type:pdf, Size:1020Kb

ATM Signalling and Cancer Oncogene (2014) 33, 3351–3360 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW ATM signalling and cancer CA Cremona and A Behrens ATM, the protein kinase mutated in the rare human disease ataxia telangiectasia (A-T), has been the focus of intense scrutiny over the past two decades. Initially this was because of the unusual radiosensitive phenotype of cells from A-T patients, and latterly because investigating ATM signalling has yielded valuable insights into the DNA damage response, redox signalling and cancer. With the recent explosion in genomic data, ATM alterations have been revealed both in the germline as a predisposing factor for cancer and as somatic changes in tumours themselves. Here we review these findings, as well as advances in the understanding of ATM signalling mechanisms in cancer and ATM inhibition as a strategy for cancer treatment. Oncogene (2014) 33, 3351–3360; doi:10.1038/onc.2013.275; published online 15 July 2013 Keywords: ATM; signalling; cancer INTRODUCTION TRRAP proteins) and FATC domains at the C terminus, the protein ATM, the gene mutated in ataxia telangiectasia (A-T), has been also contains N-terminal HEAT repeats (named after the proteins associated with cancer since its discovery, because A-T patients huntingtin, elongation factor 3, the A subunit of PP2A and TOR1) are prone to thymic lymphoma and other cancers.1 The first and a substrate-binding domain. The kinase domain is responsible explanation for this predisposition was that ATM encodes a kinase for several autophosphorylations, as well as phosphorylating the 3 central to the repair of double-strand breaks (DSBs) in DNA, hundreds of ATM substrates identified so far. The high number of thereby controlling genome stability and cell survival (reviewed in targets and extensive potential for modulation places ATM as a Shiloh2). A-T cells show radioresistant DNA synthesis—failure to signalling hub, with many different inputs and a complex output stop or slow cell-cycle progression in response to radiation subject to the actions of cofactors, substrates and feedback damage—revealing a lack of checkpoint control that clearly regulation. contributes to cancer predisposition. However, this is just one aspect of ATM’s function. Over recent years, a wealth of evidence has accumulated showing that ATM is part of many other ATM SIGNALLING signalling networks, including cell metabolism and growth, ATM signalling can be broadly divided into two categories: a oxidative stress, and chromatin remodelling, all of which can canonical pathway, which signals together with the Mre11-Rad50- affect cancer progression. These diverse effects mean that the NBS1 (MRN) complex from DSBs and activates the DNA damage predisposition to cancer of various types, and its clinical course in checkpoint, and several non-canonical modes of activation, which each case, is altered by inherited and spontaneous ATM mutations. are activated by other forms of cellular stress (Figure 2). Both Although ATM is rightly considered to be a tumour suppressor, signalling categories are likely to contribute to ATM’s role in ATM signalling can also be advantageous to cancer cells, tumour suppression. particularly in resistance to radio- and chemotherapeutic treat- ment. For this reason, ATM inhibitors have been developed for use Canonical ATM signalling at DSBs in cancer therapy. Here we will review these apparently ATM kinase is present in its inactive form as a non-covalently paradoxical ATM functions with reference to ATM signalling in 4 cancer cell and mouse models as well as human patients. linked dimer. Canonical ATM activation, in response to DSBs, involves dimer dissociation, activation of monomers and recruitment to DNA break sites. The MRN complex is required ATM—a multifunctional kinase for ATM recruitment to DSBs and efficient activation: the NBS1 The ATM protein is a very large, 370 kDa kinase encoded on subunit interacts directly with ATM, and ubiquitination of NBS1 human chromosome 11q22-23. Mouse ATM, encoded on chromo- helps ATM recruitment.5–7 The end clipping activity of MRN also some 9, is 84% identical to the human protein, and homologs contributes to ATM activation by generating short ssDNA oligos have been found in all eukaryotes. Because of its size, a detailed that associate with it.8 Ionising radiation (IR)-induced ATM atomic structure of the whole protein has not yet been activation via MRN results in the phosphorylation of a vast determined, but a combination of extensive mapping of patient network of substrates, including the key checkpoint kinase Chk2 mutations, in vitro studies and comparison with related phospha- and the tumour suppressor p53 (Figure 2). tidylinositol-like superfamily proteins has resulted in a well- ATM autophosphorylation at serine 1981 (Ser1981; equivalent defined domain structure incorporating many post-translational to Ser1987 in mice) occurs within 1 min of irradiation and is widely modification sites (Figure 1). As well as a PI3K-like serine/threonine used as a read-out of ATM activation.4,9 However, in the absence kinase, which is flanked by FAT (named after the FRAP, ATR and of MRN, ATM monomers are not phosphorylated at Ser1981 but Mammalian Genetics Lab, Cancer Research UK London Research Institute, London, UK. Correspondence: Dr A Behrens, Mammalian Genetics Lab, Cancer Research UK London Research Institute, 44 Lincoln’s Inn Fields, London WC2A 3LY, UK. E-mail: [email protected] Received 26 March 2013; revised 17 May 2013; accepted 20 May 2013; published online 15 July 2013 ATM and cancer CA Cremona and A Behrens 3352 HEAT repeats P P P P P Cys P Chromatin binding Substrate binding NLS Caspase 3 sites Leucine zipper NBS1 binding FAT PI3K FATC ATM N C 3056 a.a. 367 794 1403 1893 1981 2996 Figure 1. Domain structure of human ATM. ATM can be divided into an N-terminal half that is largely unique, and a C-terminal half that has homology to other phosphoinositide-3 kinase (PI3K)-like kinases such as ATR, mTOR and DNA-PKcs. This conserved portion contains a FAT domain (named after the FRAP, ATR, and TRRAP proteins), the PI3K-like serine/threonine kinase domain (here shown in red), and a FAT C-terminal domain (FATC). ATM contains at least five autophosphorylation sites: serines 367, 1893, 1981 and 2996, whose phosphorylation is induced after IR; and threonine 1885, which is not induced by IR.189 Cdk5 phosphorylates serine 794 in postmitotic neurons,190 and Aurora B phosphorylates serine 1403 in mitosis.191 In oxidising conditions, cysteine 2991 forms a disulphide linkage with a second ATM molecule to form a dimer.68 The N-terminal portion interacts with substrates and cofactors such as NBS1, p53, BRCA1, LKB1 and BLM; amino acids 91–97 (here shown in purple) are required for IR-induced formation of nuclear ATM foci.192 Also in the N-terminal portion are a proposed chromatin- interaction domain, a nuclear localisation sequence (NLS), two caspase 3 cleavage sites, and a putative leucine zipper region.193–195 The majority of the protein is composed of 49 HEAT repeats (named after the proteins huntingtin, elongation factor 3, the A subunit of PP2A and TOR1).196 These likely mean that ATM is highly flexible; indeed, a low-resolution structural study of ATM found a flexible arm region that changes conformation upon DNA binding.197 Diagram produced using Domain Graph 2.0.198 17–19 Canonical Non-canonical Redox damage sites. RNF168 monoubiquitylates histones H2A and Ionising Chromatin changes H2AX on lysines 13 and 15 and primes them for polyubiquity- radiation (hypotonic stress; chloroquine) Oxidation lation, necessary for recruitment of further repair factors.20 ATM and Mdc1 determine the spreading of gH2AX along chromatin, while ubiquitin enzymes control spreading of ubiquitylated histones.21,22 Continued ATM activation is required to maintain ATMATM ATM ATM ATM ATM damage foci even when ubiquitylated regions are expanded.22 A complex feedback system dynamically tunes ATM signalling to the existing damage—as long as damage persists above a threshold, ATM is activated in a pulse-like manner due to feedback 23 P P P P from activated p53. The molecular details of ATM signalling 24–26 ATM NBS1 ATM ATMIN ATM ATM at DSBs have been extensively reviewed. Here we will highlight the emerging interplay between ATM and chromatin in this response. Many groups have shown that ATM is important for the repair of DSBs at diverse genome locations, including euchromatic P P P P P 15,27,28 Chk2 Chk2 Chk2 Smc1 Smc1 immunoglobulin loci, while others have found that it is particularly required for DSBs located in heterochromatin.29,30 P P P Kap1 Kap1 ? Although experiments with laser lines show a local P P P 9 p53 p53 p53 decondensation of chromatin at DSBs that is ATM-independent, P ATM also decondenses chromatin to increase accessibility to ? • DSB repair repair machinery and reinforce its own activation. ATM-dependent • Cell cycle arrest • Genome stability phosphorylation of RNF20/RNF40 leads to ubiquitination of • Radiosensitivity • Control of cell survival • Oxidative stress response histone H2B, and ATM phosphorylation of Kap1 reduces its affinity for the chromodomain protein CHD3, both of which lead Figure 2. Canonical and non-canonical ATM signalling pathways. 31–33 ATM signals together with the MRN complex at DSBs (canonical to decompaction of chromatin structure. pathway, left); together with ATMIN following non-DSB stimuli such Chromatin relaxation at DSB sites also ensures efficient ATM as oxidative stress and chromatin changes (middle) and can also activation. It has long been known that histone deacetylase form disulphide dimers in oxidative stress conditions (right). inhibitors activate ATM,4 and Tip60 mediates acetylation of Chromatin remodelling around DSBs also contributes to canonical histones H4 and H2AX to remodel chromatin at DSB sites.34 ATM activation.
Recommended publications
  • The Functions of DNA Damage Factor RNF8 in the Pathogenesis And
    Int. J. Biol. Sci. 2019, Vol. 15 909 Ivyspring International Publisher International Journal of Biological Sciences 2019; 15(5): 909-918. doi: 10.7150/ijbs.31972 Review The Functions of DNA Damage Factor RNF8 in the Pathogenesis and Progression of Cancer Tingting Zhou 1, Fei Yi 1, Zhuo Wang 1, Qiqiang Guo 1, Jingwei Liu 1, Ning Bai 1, Xiaoman Li 1, Xiang Dong 1, Ling Ren 2, Liu Cao 1, Xiaoyu Song 1 1. Institute of Translational Medicine, China Medical University; Key Laboratory of Medical Cell Biology, Ministry of Education; Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, Shenyang, Liaoning Province, China 2. Department of Anus and Intestine Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China Corresponding authors: Xiaoyu Song, e-mail: [email protected] and Liu Cao, e-mail: [email protected]. Key Laboratory of Medical Cell Biology, Ministry of Education; Institute of Translational Medicine, China Medical University; Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, Shenyang, Liaoning Province, 110122, China. Tel: +86 24 31939636, Fax: +86 24 31939636. © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2018.12.03; Accepted: 2019.02.08; Published: 2019.03.09 Abstract The really interesting new gene (RING) finger protein 8 (RNF8) is a central factor in DNA double strand break (DSB) signal transduction.
    [Show full text]
  • Mediator of DNA Damage Checkpoint Protein 1 Facilitates V(D)J Recombination in Cells Lacking DNA Repair Factor XLF
    biomolecules Article Mediator of DNA Damage Checkpoint Protein 1 Facilitates V(D)J Recombination in Cells Lacking DNA Repair Factor XLF Carole Beck 1,2, Sergio Castañeda-Zegarra 1,2 , Camilla Huse 1,2, Mengtan Xing 1,2 and Valentyn Oksenych 1,2,3,* 1 Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway; [email protected] (C.B.); [email protected] (S.C.-Z.); [email protected] (C.H.); [email protected] (M.X.) 2 St. Olavs Hospital, Trondheim University Hospital, Clinic of Medicine, Postboks 3250 Sluppen, 7006 Trondheim, Norway 3 Department of Biosciences and Nutrition (BioNuT), Karolinska Institutet, 14183 Huddinge, Sweden * Correspondence: [email protected] Received: 27 November 2019; Accepted: 24 December 2019; Published: 30 December 2019 Abstract: DNA double-strand breaks (DSBs) trigger the Ataxia telangiectasia mutated (ATM)-dependent DNA damage response (DDR), which consists of histone H2AX, MDC1, RNF168, 53BP1, PTIP, RIF1, Rev7, and Shieldin. Early stages of B and T lymphocyte development are dependent on recombination activating gene (RAG)-induced DSBs that form the basis for further V(D)J recombination. Non-homologous end joining (NHEJ) pathway factors recognize, process, and ligate DSBs. Based on numerous loss-of-function studies, DDR factors were thought to be dispensable for the V(D)J recombination. In particular, mice lacking Mediator of DNA Damage Checkpoint Protein 1 (MDC1) possessed nearly wild-type levels of mature B and T lymphocytes in the spleen, thymus, and bone marrow. NHEJ factor XRCC4-like factor (XLF)/Cernunnos is functionally redundant with ATM, histone H2AX, and p53-binding protein 1 (53BP1) during the lymphocyte development in mice.
    [Show full text]
  • AGC Kinases in Mtor Signaling, in Mike Hall and Fuyuhiko Tamanoi: the Enzymes, Vol
    Provided for non-commercial research and educational use only. Not for reproduction, distribution or commercial use. This chapter was originally published in the book, The Enzymes, Vol .27, published by Elsevier, and the attached copy is provided by Elsevier for the author's benefit and for the benefit of the author's institution, for non-commercial research and educational use including without limitation use in instruction at your institution, sending it to specific colleagues who know you, and providing a copy to your institution’s administrator. All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier's permissions site at: http://www.elsevier.com/locate/permissionusematerial From: ESTELA JACINTO, AGC Kinases in mTOR Signaling, In Mike Hall and Fuyuhiko Tamanoi: The Enzymes, Vol. 27, Burlington: Academic Press, 2010, pp.101-128. ISBN: 978-0-12-381539-2, © Copyright 2010 Elsevier Inc, Academic Press. Author's personal copy 7 AGC Kinases in mTOR Signaling ESTELA JACINTO Department of Physiology and Biophysics UMDNJ-Robert Wood Johnson Medical School, Piscataway New Jersey, USA I. Abstract The mammalian target of rapamycin (mTOR), a protein kinase with homology to lipid kinases, orchestrates cellular responses to growth and stress signals. Various extracellular and intracellular inputs to mTOR are known. mTOR processes these inputs as part of two mTOR protein com- plexes, mTORC1 or mTORC2. Surprisingly, despite the many cellular functions that are linked to mTOR, there are very few direct mTOR substrates identified to date.
    [Show full text]
  • DNA Repair and Synthetic Lethality
    Int J Oral Sci (2011) 3:176-179. www.ijos.org.cn REVIEW DNA repair and synthetic lethality Gong-she Guo1, Feng-mei Zhang1, Rui-jie Gao2, Robert Delsite4, Zhi-hui Feng1,3*, Simon N. Powell4* 1School of Public Health, Shandong University, Jinan 250012, China; 2Second People’s Hospital of Weifang, Weifang 261041, China; 3Department of Radiation Oncology, Washington University in St Louis, St Louis MO 63108, USA; 4Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York NY 10065, USA Tumors often have DNA repair defects, suggesting additional inhibition of other DNA repair pathways in tumors may lead to synthetic lethality. Accumulating data demonstrate that DNA repair-defective tumors, in particular homologous recombination (HR), are highly sensitive to DNA-damaging agents. Thus, HR-defective tumors exhibit potential vulnerability to the synthetic lethality approach, which may lead to new therapeutic strategies. It is well known that poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitors show the synthetically lethal effect in tumors defective in BRCA1 or BRCA2 genes encoded proteins that are required for efficient HR. In this review, we summarize the strategies of targeting DNA repair pathways and other DNA metabolic functions to cause synthetic lethality in HR-defective tumor cells. Keywords: DNA repair; homologous recombination; synthetic lethality; BRCA; Rad52 International Journal of Oral Science (2011) 3: 176-179. doi: 10.4248/IJOS11064 Introduction polymerase (PARP) inhibitors are specifically toxic to homologous recombination (HR)-defective cells [3-4]. Synthetic lethality is defined as a genetic combination Playing a key role in maintaining genetic stability, HR is of mutations in two or more genes that leads to cell a major repair pathway for double-strand breaks (DSBs) death, whereas a mutation in any one of the genes does utilizing undamaged homologous DNA sequence [5-6].
    [Show full text]
  • Phosphatidylinositol-3-Kinase Related Kinases (Pikks) in Radiation-Induced Dna Damage
    Mil. Med. Sci. Lett. (Voj. Zdrav. Listy) 2012, vol. 81(4), p. 177-187 ISSN 0372-7025 DOI: 10.31482/mmsl.2012.025 REVIEW ARTICLE PHOSPHATIDYLINOSITOL-3-KINASE RELATED KINASES (PIKKS) IN RADIATION-INDUCED DNA DAMAGE Ales Tichy 1, Kamila Durisova 1, Eva Novotna 1, Lenka Zarybnicka 1, Jirina Vavrova 1, Jaroslav Pejchal 2, Zuzana Sinkorova 1 1 Department of Radiobiology, Faculty of Health Sciences in Hradec Králové, University of Defence in Brno, Czech Republic 2 Centrum of Advanced Studies, Faculty of Health Sciences in Hradec Králové, University of Defence in Brno, Czech Republic. Received 5 th September 2012. Revised 27 th November 2012. Published 7 th December 2012. Summary This review describes a drug target for cancer therapy, family of phosphatidylinositol-3 kinase related kinases (PIKKs), and it gives a comprehensive review of recent information. Besides general information about phosphatidylinositol-3 kinase superfamily, it characterizes a DNA-damage response pathway since it is monitored by PIKKs. Key words: PIKKs; ATM; ATR; DNA-PK; Ionising radiation; DNA-repair ABBREVIATIONS therapy and radiation play a pivotal role. Since cancer is one of the leading causes of death worldwide, it is DSB - double stand breaks, reasonable to invest time and resources in the enligh - IR - ionising radiation, tening of mechanisms, which underlie radio-resis - p53 - TP53 tumour suppressors, tance. PI - phosphatidylinositol. The aim of this review is to describe the family INTRODUCTION of phosphatidyinositol 3-kinases (PI3K) and its func - tional subgroup - phosphatidylinositol-3-kinase rela - An efficient cancer treatment means to restore ted kinases (PIKKs) and their relation to repairing of controlled tissue growth via interfering with cell sig - radiation-induced DNA damage.
    [Show full text]
  • Polo-Like Kinase 1 in Genomic Instability
    Polo-like Kinase 1 in genomic instability Xiaoqi Liu Department of Toxicology and Cancer Biology University of Kentucky The fate of a single parental chromosome throughout the eukaryotic cell cycle Cytokinesis Activation of cell division Preparation for mitosis The stages of mitosis and cytokinesis in an animal cell MT MT - + kinetochore Centrosome Spindle pole + (MTOC) Spindle pole Centrosome Spindle Nucleus G2 Prophase Prometaphase Metaphase Central spindle Contractile ring Midbody Anaphase Telophase Cytokinesis Control of mitotic entry and exit by Cdc2/cyclin B and APC Anaphase promoting complex (APC) Cdc2 Cyclin B Cdc2 Anaphase inhibitor Cyclin B Cdc2 G2 Prophase Metaphase Anaphase Telophase G1 (Liu & Erikson, PNAS 2002; Liu & Erikson, PNAS 2003; Liu et al, MCB 2005; Liu et al, MCB 2006) The polo-like kinases have a C-terminal polo-box domain M-phase kinase domain polo-box Plk1 603 Plx1 (Xl) 80% 598 polo (Dm) 65% 576 Plo1 (Sp) 50% 683 Cdc5 (Sc) 51% 705 Early phase of cell cycle Plk2 52% 683 Plk3 52% 631 Plk1 localizes to mitotic structures G2/pro Prometa Spindle poles Centrosomes kinetochores Centrosomes Centrosomes kinetochores Meta Telo Spindle poles Midbodies kinetochores Spindle poles Central spindles kinetochores Plk1 in cancer ---Plk1 overexpression is correlated with cell proliferation and carcinogenesis. ---Plk1 is a new diagnostic marker for cancer. ---Plk1 inhibitors are in various clinical trails. ---However, how Plk1 contributes to carcinogenesis is elusive. Does Plk1 elevation contribute to cancer progression? Approach:
    [Show full text]
  • A Balanced Transcription Between Telomerase and the Telomeric DNA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by HAL-ENS-LYON A balanced transcription between telomerase and the telomeric DNA-binding proteins TRF1, TRF2 and Pot1 in resting, activated, HTLV-1-transformed and Tax-expressing human T lymphocytes. Emmanuelle Escoffier, Am´elieRezza, Aude Roborel de Climens, Aur´elie Belleville, Louis Gazzolo, Eric Gilson, Madeleine Duc Dodon To cite this version: Emmanuelle Escoffier, Am´elieRezza, Aude Roborel de Climens, Aur´elieBelleville, Louis Gaz- zolo, et al.. A balanced transcription between telomerase and the telomeric DNA-binding proteins TRF1, TRF2 and Pot1 in resting, activated, HTLV-1-transformed and Tax-expressing human T lymphocytes.. Retrovirology, BioMed Central, 2005, 2, pp.77. <10.1186/1742-4690- 2-77>. <inserm-00089278> HAL Id: inserm-00089278 http://www.hal.inserm.fr/inserm-00089278 Submitted on 16 Aug 2006 HAL is a multi-disciplinary open access L'archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destin´eeau d´ep^otet `ala diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publi´esou non, lished or not. The documents may come from ´emanant des ´etablissements d'enseignement et de teaching and research institutions in France or recherche fran¸caisou ´etrangers,des laboratoires abroad, or from public or private research centers. publics ou priv´es. Retrovirology BioMed Central Research Open Access A balanced transcription between telomerase and the
    [Show full text]
  • Anti-TERF2 / Trf2 Antibody (ARG59099)
    Product datasheet [email protected] ARG59099 Package: 50 μg anti-TERF2 / Trf2 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes TERF2 / Trf2 Tested Reactivity Hu, Rat Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name TERF2 / Trf2 Antigen Species Human Immunogen Recombinant protein corresponding to A81-K287 of Human TERF2 / Trf2. Conjugation Un-conjugated Alternate Names Telomeric DNA-binding protein; TRF2; TTAGGG repeat-binding factor 2; TRBF2; Telomeric repeat- binding factor 2 Application Instructions Application table Application Dilution IHC-P 0.5 - 1 µg/ml WB 0.1 - 0.5 µg/ml Application Note IHC-P: Antigen Retrieval: By heat mediation. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 60 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.9% NaCl, 0.2% Na2HPO4, 0.05% Sodium azide and 5% BSA. Preservative 0.05% Sodium azide Stabilizer 5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol TERF2 Gene Full Name telomeric repeat binding factor 2 Background This gene encodes a telomere specific protein, TERF2, which is a component of the telomere nucleoprotein complex.
    [Show full text]
  • Molecular Anatomy and Regulation of a Stable Replisome at a Paused Eukaryotic DNA Replication Fork
    Downloaded from genesdev.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press Molecular anatomy and regulation of a stable replisome at a paused eukaryotic DNA replication fork Arturo Calzada,1,2,3 Ben Hodgson,1,3 Masato Kanemaki,1 Avelino Bueno,2 and Karim Labib1,4 1Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, United Kingdom; 2Cancer Research Institute, University of Salamanca/CSIC, 37007 Salamanca, Spain Eukaryotic cells regulate the progression and integrity of DNA replication forks to maintain genomic stability and couple DNA synthesis to other processes. The budding yeast proteins Mrc1 and Tof1 associate with the putative MCM–Cdc45 helicase and limit progression of the replisome when nucleotides are depleted, and the checkpoint kinases Mec1 and Rad53 stabilize such stalled forks and prevent disassembly of the replisome. Forks also pause transiently during unperturbed chromosome replication, at sites where nonnucleosomal proteins bind DNA tightly. We describe a method for inducing prolonged pausing of forks at protein barriers assembled at unique sites on a yeast chromosome, allowing us to examine for the first time the effects of pausing upon replisome integrity. We show that paused forks maintain an intact replisome that contains Mrc1, Tof1, MCM–Cdc45, GINS, and DNA polymerases ␣ and ␧ and that recruits the Rrm3 helicase. Surprisingly, pausing does not require Mrc1, although Tof1 and Csm3 are both important. In addition, the integrity of the paused forks does not require Mec1, Rad53, or recombination. We also show that paused forks at analogous barriers in the rDNA are regulated similarly. These data indicate that paused and stalled eukaryotic replisomes resemble each other but are regulated differently.
    [Show full text]
  • Incision of Damaged DNA in the Presence of an Impaired Smc5/6 Complex Imperils Genome Stability Jie Peng and Wenyi Feng*
    10216–10229 Nucleic Acids Research, 2016, Vol. 44, No. 21 Published online 17 August 2016 doi: 10.1093/nar/gkw720 Incision of damaged DNA in the presence of an impaired Smc5/6 complex imperils genome stability Jie Peng and Wenyi Feng* Department of Biochemistry and Molecular Biology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA Received February 01, 2016; Revised August 05, 2016; Accepted August 08, 2016 ABSTRACT cleotide excision repair (RER) pathways, respectively (7). / Virtually all DNA repair pathways require recognition and The Smc5 6 complex is implicated in homologous subsequent excisions of the damaged nucleotide, giving rise recombination-mediated DNA repair during DNA to a single-stranded gap in the DNA polymer (7). The mech- damage or replication stress. Here, we analysed anisms ensuring such a structural alteration of the chro- genome-wide replication dynamics in a hypomorphic mosome is efficiently repaired and does not lead to further budding yeast mutant, smc6-P4. The overall replica- degradation are underexplored. Conceivably, these mecha- tion dynamics in the smc6 mutant is similar to that nisms would involve protein complexes directly interacting in the wild-type cells. However, we captured a dif- with the chromosomal DNA and implicated in DNA dam- ference in the replication profile of an early S phase age or replication stress response. sample in the mutant, prompting the hypothesis that One of the three evolutionarily conserved Structure the mutant incorporates ribonucleotides and/or ac- Maintenance of Chromosome (SMC) protein complexes, the Smc5/6 complex, plays a key role in DNA damage re- cumulates single-stranded DNA gaps during replica- pair.
    [Show full text]
  • The Tumor Therapy Landscape of Synthetic Lethality
    ARTICLE https://doi.org/10.1038/s41467-021-21544-2 OPEN The tumor therapy landscape of synthetic lethality Biyu Zhang1,4, Chen Tang1,4, Yanli Yao2,4, Xiaohan Chen1, Chi Zhou 1, Zhiting Wei1, Feiyang Xing1, Lan Chen2, ✉ ✉ Xiang Cai3, Zhiyuan Zhang2, Shuyang Sun 2 & Qi Liu 1 Synthetic lethality is emerging as an important cancer therapeutic paradigm, while the comprehensive selective treatment opportunities for various tumors have not yet been explored. We develop the Synthetic Lethality Knowledge Graph (SLKG), presenting the tumor therapy landscape of synthetic lethality (SL) and synthetic dosage lethality (SDL). SLKG 1234567890():,; integrates the large-scale entity of different tumors, drugs and drug targets by exploring a comprehensive set of SL and SDL pairs. The overall therapy landscape is prioritized to identify the best repurposable drug candidates and drug combinations with literature supports, in vitro pharmacologic evidence or clinical trial records. Finally, cladribine, an FDA-approved multiple sclerosis treatment drug, is selected and identified as a repurposable drug for treating melanoma with CDKN2A mutation by in vitro validation, serving as a demonstrating SLKG utility example for novel tumor therapy discovery. Collectively, SLKG forms the com- putational basis to uncover cancer-specific susceptibilities and therapy strategies based on the principle of synthetic lethality. 1 Translational Medical Center for Stem Cell Therapy and Institute for Regenerative Medicine, Shanghai East Hospital, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai, China. 2 Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
    [Show full text]
  • Diverse Mechanisms Activate the PI 3-Kinase/Mtor Pathway In
    Tran et al. BMC Cancer (2021) 21:136 https://doi.org/10.1186/s12885-021-07826-4 RESEARCH ARTICLE Open Access Diverse mechanisms activate the PI 3- kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK Khanh B. Tran1,2,3, Sharada Kolekar1, Anower Jabed2, Patrick Jaynes2, Jen-Hsing Shih2, Qian Wang2, Jack U. Flanagan1,3, Gordon W. Rewcastle1,3, Bruce C. Baguley1,3 and Peter R. Shepherd1,2,3* Abstract Background: The PI 3-kinase (PI3K) pathway has been implicated as a target for melanoma therapy. Methods: Given the high degree of genetic heterogeneity in melanoma, we sought to understand the breadth of variation in PI3K signalling in the large NZM panel of early passage cell lines developed from metastatic melanomas. Results: We find the vast majority of lines show upregulation of this pathway, and this upregulation is achieved by a wide range of mechanisms. Expression of all class-IA PI3K isoforms was readily detected in these cell lines. A range of genetic changes in different components of the PI3K pathway was seen in different lines. Coding variants or amplification were identified in the PIK3CA gene, and amplification of the PK3CG gene was common. Deletions in the PIK3R1 and PIK3R2 regulatory subunits were also relatively common. Notably, no genetic variants were seen in the PIK3CD gene despite p110δ being expressed in many of the lines. Genetic variants were detected in a number of genes that encode phosphatases regulating the PI3K signalling, with reductions in copy number common in PTEN, INPP4B, INPP5J, PHLLP1 and PHLLP2 genes.
    [Show full text]